Data / Drug companies / Atlantic Biologicals Corp.
Atlantic Biologicals Corp.: 126 products in the FDA NDC directory, labeler code 17856
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Atlantic Biologicals Corp. (labeler code 17856) lists 126 products in the FDA National Drug Code Directory, covering 83 finished drugs by generic name. By type: 73 prescription drugs, 53 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 7, 2025.
The request: Watch Atlantic Biologicals Corp. (FDA labeler code 17856): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 17856
- Products in commercial distribution
- 126
- Packages
- 280
- Finished drugs by generic name
- 83
- Prescription products
- 73
- Over the counter products
- 53
- Controlled substance products
- Schedule II 2, Schedule IV 1, Schedule V 1
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- January 1, 1969
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 80 | 63.5% |
| Over the counter monograph drugs | 36 | 28.6% |
| Other unapproved drugs | 5 | 4% |
| Authorized generics (NDA) | 3 | 2.4% |
| New drug applications (NDA) | 2 | 1.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 73 | 57.9% |
| Over the counter drugs | 53 | 42.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 39 | 31% |
| Suspension | 23 | 18.3% |
| Liquid | 13 | 10.3% |
| Syrup | 8 | 6.3% |
| Lozenge | 6 | 4.8% |
| Tablet, film coated | 5 | 4% |
| Rinse | 3 | 2.4% |
| Tablet, extended release | 3 | 2.4% |
| Tablet, chewable | 3 | 2.4% |
| Elixir | 3 | 2.4% |
| Tablet, delayed release | 3 | 2.4% |
| Powder, for solution | 2 | 1.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Promethazine Hydrochloride and Dextromethorphan Hydrobromide | 17856-4024 | Syrup | Generic drugs (ANDA) | April 7, 2025 |
| Promethazine hydrochloride | 17856-4023 | Syrup | Generic drugs (ANDA) | April 7, 2025 |
| Dicyclomine Hydrochloride | 17856-2261 | Solution | Generic drugs (ANDA) | March 4, 2025 |
| SIMETHICONE INFANT Gas Relief Drops | 17856-1018 | Suspension | Over the counter monograph drugs | February 20, 2025 |
| SIMETHICONE INFANT Gas Relief Drops | 17856-1017 | Suspension | Over the counter monograph drugs | February 20, 2025 |
| MAX relief junior Grape | 17856-1125 | Liquid | Over the counter monograph drugs | July 1, 2024 |
| MAX relief junior Grape | 17856-1123 | Liquid | Over the counter monograph drugs | July 1, 2024 |
| MAX relief junior Grape | 17856-1122 | Liquid | Over the counter monograph drugs | July 1, 2024 |
| OneLAX SENNA | 17856-8127 | Syrup | Over the counter monograph drugs | February 6, 2024 |
| OneLAX SENNA | 17856-1127 | Syrup | Over the counter monograph drugs | February 6, 2024 |
| Cyproheptadine hydrochloride | 17856-1185 | Solution | Generic drugs (ANDA) | December 22, 2023 |
| Aripiprazole | 17856-0684 | Solution | Generic drugs (ANDA) | November 1, 2023 |
| Spironolactone | 17856-1233 | Suspension | Authorized generics (NDA) | October 31, 2023 |
| Spironolactone | 17856-1133 | Suspension | Authorized generics (NDA) | October 31, 2023 |
| Baclofen | 17856-0620 | Solution | Authorized generics (NDA) | October 12, 2023 |
| Prednisolone Sodium Phosphate | 17856-8815 | Solution | Generic drugs (ANDA) | October 9, 2023 |
| Prednisolone Sodium Phosphate | 17856-0815 | Solution | Generic drugs (ANDA) | October 9, 2023 |
| Potassium chloride | 17856-0048 | Solution | Generic drugs (ANDA) | October 5, 2023 |
| TEENY TUMMY Gas Relief Drops | 17856-1142 | Suspension | Over the counter monograph drugs | August 4, 2023 |
| TEENY TUMMY Gas Relief Drops | 17856-1141 | Suspension | Over the counter monograph drugs | August 4, 2023 |
| Chlorhexidine Gluconate Oral Rinse | 17856-2128 | Solution | Generic drugs (ANDA) | July 27, 2023 |
| MAX Tussin Cough and Chest Congestion DM Sugar Free | 17856-1126 | Liquid | Over the counter monograph drugs | May 15, 2023 |
| MAX relief junior | 17856-0046 | Liquid | Over the counter monograph drugs | May 14, 2023 |
| MAX relief junior | 17856-0045 | Liquid | Over the counter monograph drugs | May 14, 2023 |
| MAX relief junior | 17856-0025 | Liquid | Over the counter monograph drugs | May 14, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.